Characterization of SPINK1 in Prostate Cancer PRINCIPAL INVESTIGATOR:

Characterization of SPINK1 in Prostate Cancer

XWH - 10 - 1 - 0590 TITLE : Global Characterization of Protein - Altering Mutations in Prostate Cancer PRINCIPAL

Award Number: W81XWH-10-1-0590 TITLE: Global Characterization of Protein-Altering Mutations in Prostate Cancer PRINCIPAL INVESTIGATOR: Peter S. Nelson, MD CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109-1024 REPORT DATE: August 2012 TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTI...

Characterization of the TMPRSS2 Protease as a Modulator of Prostate Cancer Metastasis PRINCIPAL INVESTIGATOR:

SPINK1 protein expression and prostate cancer progression.

PURPOSE SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer-specific survival. EXPERIMENTAL DESIGN The study included 879 participants in the U.S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnose...

SPINK1: a new therapeutic target in cancer?

The serine protease inhibitor Kazal type 1 (SPINK1) was initially isolated from bovine pancreas by Kazal and colleagues. A similar protease inhibitor was later identified in human pancreatic juice and called “pancreatic secretory trypsin inhibitor.” By means of immunologic techniques, SPINK1 was later identified as a tumor-associated peptide and isolated from the urine of a patient with ovarian...